The public record of what the powerful say about the futureAll times UTCYour time ATHENA News Room is liveSealed daily · anchored in BitcoinΕλληνικά A Tekmerion product
THE ORACLE HUNTERS • EVERY PROPHECY ON THE RECORD •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The Oracle HuntersEvery prophecy, on the record. · Οἱ Κυνηγοὶ τῶν ΧρησμῶνUnder development

← Tracking the Prophets

Moderna

Institution - official statements with no named speaker · USA

Track record: No forecast checked yet (52 not due, 79 being checked).
131forecasts & commitments on the record
56%can be checked as stated
36average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns

Timeline

20192019: Due - being checked2019: Due - being checked2019: Due - being checked2019: Due - being checked2019: Due - being checked20202020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked (+2 more)20212021: Not due yet2021: Due - being checked2021: Due - being checked2021: Due - being checked2021: Due - being checked2021: Due - being checked2021: Not due yet2021: Due - being checked (+12 more)20222022: Due - being checked2022: Due - being checked2022: Due - being checked2022: Due - being checked2022: Not due yet2022: Not due yet2022: Due - being checked2022: Due - being checked (+7 more)20232023: Due - being checked2023: Due - being checked2023: Due - being checked2023: Due - being checked2023: Due - being checked2023: Due - being checked2023: Due - being checked2023: Not due yet (+13 more)20242024: Due - being checked2024: Due - being checked2024: Due - being checked2024: Due - being checked2024: Not due yet2024: Due - being checked2024: Due - being checked2024: Due - being checked (+11 more)20252025: Not due yet2025: Not due yet2025: Not due yet2025: Due - being checked2025: Due - being checked2025: Due - being checked2025: Due - being checked2025: Due - being checked (+13 more)20262026: Not due yet2026: Not due yet2026: Not due yet2026: Not due yet2026: Not due yet2026: Not due yet2026: Not due yet2026: Not due yet (+12 more)
came true partly did not not due / being checked / too vague

Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 129, stated on authority 2.
Kinds of claim: forecast 123, mixed claim 6, commitment 2. · Download this report card as a picture

In the nine words

πρόγνωσιςInference from evidence126 · 96%μαντείαInspired knowledge2 · 2%χρησμοδοσίαInstitutional delivery2 · 2%πρόβλεψιςSeeing the signs1 · 1%
How to read this Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.

On the record (131)

This outlook excludes additional drawdowns from the approximately $0.9 billion remaining available under the Company's credit facility.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standardNot due yetfinance
“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standardNot due yetgrowth
Revenue: The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth.
Increases 2026 expected revenue growth to 15%–25%, exceeding the previous expectation of up to 10% growth
Cash and Investments: The Company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Capital Expenditures: Capital expenditures for 2026 are expected to be approximately $0.2 billion, improved from the previous expectation of $0.2 billion to $0.3 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international.
Cash and Investments: Year-end cash and investments for 2026 are now projected to be $4.7 to $5.2 billion, an improvement of approximately $0.2 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
"In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs."
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yettrade
Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Cash and Investments: Year-end cash and investments for 2026 are now projected to be $4.5 to $5.0 billion, which excludes any further drawdowns from the Company's remaining $0.9 billion available under its credit facility.
πρόγνωσις · Inference from evidenceCan be checkedForecastbased on dataambiguity 0/100implied call / likelihood: Yes · 70% · probablemeets the RIM-1 standarddue 31 Dec 2026Not due yetfinance
Moderna is entering the year with three approved products, Spikevax®, mNEXSPIKE® and mRESVIA®, with seasonal vaccines expected to deliver up to 10% revenue growth in 2026.
Cash and Investments: Year-end cash and investments for 2026 are projected to be $5.5 to $6.0 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Moderna’s 2026 financial framework, including projected up to 10% revenue growth and expected operating expenses;
•Moderna announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial to help advance Moderna's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.
We expect this approach to support up to 10 percent revenue growth in 2026, as we further reduce costs, expand our commercial portfolio with approvals of additional seasonal vaccines, and anticipate multiple clinical data catalysts driven by our late-stage oncology pipeline.”
Moderna expects to further reduce GAAP operating expenses to $4.2 – $4.6 billion in 2027, on the path to targeted cash breakeven in 2028.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2027Not due yet
Increases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited)
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
The Company expects to start a registrational study in 2026.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
The Company expects to complete submissions for approval of mRNA-1010 in the U.S., Canada, Australia and Europe by January 2026.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
•Norovirus vaccine: Moderna's ongoing Phase 3 safety and efficacy study of its trivalent vaccine against norovirus (mRNA-1403) has not accrued sufficient cases and will now enroll a second Northern Hemisphere season (2025-2026) for additional case accruals.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2026Not due yethealth
Cash and Investments: Year-end cash and investments for 2025 are projected to be $6.5 to $7 billion, increased from previous expectations of approximately $6 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Cash and Investments: Year-end cash and investments for 2025 are projected to be approximately $6 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion, lowered from previous expectations of approximately $0.4 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
“Today, we are updating our 2025 financial framework, reducing the high end of this year's expected revenue range by $300 million due to the timing of shipments.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Reiterates 2025 expected year-end cash balance of approximately $6 billion
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Mar 2026Due - being checked
Based on FDA feedback confirming the need for Phase 3 flu efficacy data, Moderna expects an extended review timeline and is now targeting approval in 2026.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Moderna is expanding its cost efficiency and prioritization programs and expects estimated GAAP operating costs of $5.4 to $5.7 billion in 2026, a reduction from the Company’s previous estimate of $5.9 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.4 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
“Looking ahead, we are reiterating our 2025 financial framework and announcing a cost structure that is expected to reduce our annual operating expenses by approximately $1.5 billion by 2027.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2027Not due yet
Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
By the end of 2025, we aim to remove nearly $1 billion in costs.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standarddue 31 Dec 2025Due - being checked
With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth.”
πρόγνωσις · Inference from evidenceCan be checkedForecastbased on dataambiguity 0/100implied call / likelihood: Yes · 70% · probablemeets the RIM-1 standarddue 31 Dec 2025Due - being checkedgrowth
The Company expects to end 2025 with cash and investments of approximately $6.0 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
The Company expects an additional $0.5 billion in potential cash cost savings in 2026.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2026Not due yet
The Company expects to start a pivotal study in the first half of 2025.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
•Cytomegalovirus (CMV) vaccine: Moderna expects to have accrued the 81 cases necessary to trigger the first interim analysis of the Phase 3 vaccine efficacy study of its CMV vaccine candidate (mRNA-1647) by the end of 2024.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checkedhealth
Cash and Investments: Year-end cash and investments for 2024 are projected to be approximately $9 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checked
Capital Expenditures: Capital expenditures for 2024 are now expected to be approximately $1.2 billion (previously ~$0.9 billion).
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checked
•Received a project award of $176 million through BARDA's Rapid Response Partnership Vehicle Consortium to accelerate the development of an mRNA-based pandemic influenza vaccine.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standardNot due yethealth
Capital Expenditures: Capital expenditures for 2024 are expected to be approximately $0.9 billion.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checked
The first interim analysis for the evaluation of vaccine efficacy is expected as early as the end of 2024.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checkedhealth
“With 10 late-stage programs, and additional new programs advancing toward pivotal studies, we continue to expect numerous product milestones this year across our vaccines and therapeutics portfolio.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checkedhealth
“As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline and have intensified our focus on building and utilizing AI technologies to further streamline operations and enhance productivity,” said Stéphane Bancel, Chief Executive Officer of Moderna.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checkedaihealth

Showing the newest 50 - the ledger has all 131.